10-QPeriod: Q2 FY2025

QUEST DIAGNOSTICS INC Quarterly Report for Q2 Ended Jun 30, 2025

Filed July 23, 2025For Securities:DGX

Summary

Quest Diagnostics Inc. reported strong financial performance for the second quarter and first six months of 2025, with net revenues increasing significantly year-over-year, primarily driven by its Diagnostic Information Services (DIS) segment. This growth was fueled by a substantial increase in requisition volume, largely attributed to recent acquisitions, alongside positive organic growth. The company also saw an increase in revenue per requisition on an organic basis, indicating improving test mix and utilization. Profitability also showed a marked improvement, with operating income and net income attributable to Quest Diagnostics rising considerably. This was supported by effective cost management, including savings from the 'Invigorate' program, though partially offset by increased costs associated with acquisitions and wage inflation. The company continues to manage its capital structure prudently, with healthy cash flow from operations and significant available borrowing capacity. Looking ahead, Quest Diagnostics is navigating evolving healthcare legislation, such as the One Big Beautiful Bill Act, and currently anticipates a minimal material impact on its consolidated revenues in the near term.

Financial Highlights

55 data points
Beta

Revenue

$2.76B

34.2% Gross Margin

Net Income

$282.00M

10.2% Net Margin

EPS (Diluted)

$2.47

Total Assets

$15.97B

Cash & Equivalents

$319.00M

Free Cash Flow

$436.00M

Financial Statements
Beta
Revenue$2.76B
Cost of Revenue$1.82B
Gross Profit$943.00M
SG&A Expenses$486.00M
Operating Expenses$2.32B
Operating Income$438.00M
Net Income$282.00M
EPS (Basic)$2.51
EPS (Diluted)$2.47
Shares Outstanding (Basic)112.00M
Shares Outstanding (Diluted)113.00M

Key Highlights

  • 1Net revenues for Q2 2025 increased by 15.2% to $2.76 billion, and for the first six months by 13.7% to $5.41 billion, driven by the DIS segment.
  • 2DIS segment revenue grew 15.7% in Q2 and 14.2% year-to-date, with requisition volume up significantly due to acquisitions and organic growth.
  • 3Operating income rose by 23.3% in Q2 to $438 million and by 19.7% year-to-date to $784 million, indicating improved profitability.
  • 4Diluted earnings per share (EPS) increased to $2.47 in Q2 2025, up from $2.03 in Q2 2024, and $4.41 year-to-date, up from $3.75.
  • 5Net cash provided by operating activities was $858 million for the first six months of 2025, a substantial increase from $514 million in the prior year period.
  • 6The company is managing its debt effectively, with $1.3 billion in available borrowing capacity under its credit facilities as of June 30, 2025.
  • 7A $24 million impairment charge on certain long-lived assets related to a potential business exit was recorded in Q2 2025.

Frequently Asked Questions

The significant increase in net revenues was primarily driven by the Diagnostic Information Services (DIS) segment, which saw a 15.7% rise year-over-year. This growth was fueled by both recent acquisitions contributing approximately 10.3% to DIS revenues and organic growth. Specifically, requisition volume increased by 16.3%, with organic volume up by 2.1%.

Quest Diagnostics demonstrated improved profitability, with operating income increasing by 23.3% to $438 million and net income attributable to Quest Diagnostics rising by 23.1% to $282 million in the second quarter of 2025 compared to the prior year. Diluted earnings per share also increased to $2.47 from $2.03.

The 'Invigorate' program aims to deliver 3% annual cost savings and productivity improvements. While this program helps offset inflationary pressures and acquisition-related costs, the company did incur increased costs of services and selling, general, and administrative expenses due to recent acquisitions and wage increases. For instance, cost of services increased by $225 million in Q2, largely driven by acquisitions and wage increases, partially offset by Invigorate program savings.

Quest Diagnostics is assessing the impact of the OBBBA and the expiration of enhanced Premium Tax Credits. Currently, the company believes these legislative changes are unlikely to have a material impact on its consolidated revenues for 2025 and 2026. However, they could potentially reduce consolidated revenues by 50-60 basis points by 2028 compared to 2025, primarily affecting ACA-related Exchange Plan revenues. The tax provisions of the OBBBA are not expected to materially impact the statement of operations.